Radiation Enhancement Ratio (RER) for Methotrexate, Paclitaxel, and Doxorubicin on Human Breast Cancer Cells When Combined with 111In-NLS-Trastuzumab
| Cell line | Methotrexate | Paclitaxel | Doxorubicin |
|---|---|---|---|
| MDA-MB-231 | 1.0 | 1.0 | 1.1 |
| 231-H2N | 2.2 | 1.6 | 2.7 |
| TrR1 | 2.0 | 1.8 | 2.8 |
| TrR2 | 1.0 | 1.0 | 1.0 |
RERs were determined by dividing SF of cells treated with 111In-NLS-trastuzumab alone (∼0.2 MBq/μg, 100 nmol/L) by that of cells treated concurrently with 111In-NLS-trastuzumab and IC10 dose for methotrexate, paclitaxel, or doxorubicin. IC10 values for each drug on each cell line are shown in Table 1.